CS Paper Radar

Computational De Novo Design of Miniprotein Candidate Neutralizers Targeting the IL-23 Cytokine Subunit p19

Raghav Paladugu, Fardina Fathmiul Alam

cs.LG q-bio.BM ·submitted 2026-10-23 15:26 UTC · v1
published

Abstract

Interleukin-23 (IL-23) drives T-helper-17 inflammation underlying inflammatory bowel disease and psoriasis; anti-p19 antibodies are clinically effective but large, costly, and injectable. De novo miniproteins are an attractive alternative, yet published designs target the IL-23 receptor; the IL-23 cytokine itself has not been addressed. A further obstacle is that the standard confidence score (ipTM) tracks construct length rather than interface quality. We computationally design miniprotein binders against the IL-23R-binding face of p19 (PDB 3DUH) and score every design with ipSAE, a length-robust interface metric derived from AlphaFold-initial-guess predicted aligned error. A conventional RFdiffusion/ProteinMPNN/ColabFold pipeline yields no reliable predicted interface across 972 designs (best ipSAE 0.30), and a scoring artifact, in which single-sequence ColabFold under-rates binder pLDDT by approximately 56 points, explains an earlier misleading "binders do not fold" signal. An interface-optimized hallucination method (BindCraft), scored identically, yields 42 of 50 designs above ipSAE 0.60 (best 0.804). An AlphaFold-independent geometric check reproduces the conventional failure: no top-ranked conventional design reaches the buried area or interface hydrogen-bond count of the weakest lead. Five all-alpha-helical leads (72-104 residues) collectively engage all six targeted hotspots; two dock within the intact p40/p19 heterodimer and all show favorable Rosetta energetics. A p40-alone counter-screen returns ipSAE 0.00 for all five, indicating no spurious p40 interface. To our knowledge, these are the first computationally proposed de novo miniprotein candidates designed to occlude the IL-23R-binding face of IL-23 p19. All results require experimental validation.

Comment
Accepted as a short paper at the 2026 IEEE International Conference on Bioinformatics and Biomedicine (BIBM 2026)

Closest papers

Nearest neighbours by meaning across the whole index.

ProteoCraft: Protein Design as Proposal-Verification Search

cs.CE cs.AIq-bio.BM ·2026-11-02 ·Fang Wu, Hongbin Lin, Bingchen Duan, Yuchen Wang, Li Erran Li +22 more
code/data similarity 0.64
Abstract

Protein-protein interactions underpin nearly all biological processes. Yet, designing proteins with desired interactions remains challenging due to the structural complexity governing molecular recognition. This study views protein design as a search optimization problem over a combinatorial sequence space under expensive structural evaluation. Toward this goal, we introduce a novel tree-based search framework, ProteoCraft, that employs approximate structural gradients from diffusion-based structure predictors as effective proposal policies to specify where the search should explore. Complete no-gradient inference of folding models separately assigns values to the resulting sequences, determining what is good. ProteoCraft allocates this verification budget through a coarse-to-fine paradigm: multi-site edits first explore distinct sequence basins, then verified promising states undergo strict single-site refinement. Across fourteen de novo binder-design settings spanning eight target proteins, five immune-relevant TCR-facing targets, and four localized CDR redesign tasks, ProteoCraft improves design quality and high-confidence yield. These improvements persist under independent AF2-IG and Rosetta-based interface evaluation. Prospective experimental validation further yielded an 82.9% binding hit rate for PD-L1 miniproteins, with a best measured KD of 0.879 nM, and confirmed binding of designed IFNAR2 VHH. Our code is available at https://github.com/smiles724/ProteoCraft_v1.

0.28

EMBER: Predicting TCR--pMHC Binding Without a Docked Complex

cs.LG q-bio.QM ·2026-10-19 ·Lin Ha, Chen Zhou, Haozheng Luo, Han Liu, Xiaoyu Zhang +1 more
hot direction similarity 0.56
Abstract

We propose EMBER, a structure-based framework for TCR--pMHC binding prediction that eliminates the need for a predicted docked complex, and with it the placement error that dominates such predictions. Traditional structure-based predictors utilize the co-folded complex structure of the receptor and the antigen and interpret binding from its contact surface. Consequently, every downstream feature inherits any deviation the structure-prediction tool introduced. Methodologically, EMBER folds the TCR and pMHC independently, encodes them as SE(3)-invariant residue graphs, and compares their learned representations without constructing a shared coordinate frame. A relative pose is therefore not an input of the model, so placement error cannot propagate into the prediction. Computationally, EMBER preprocesses $O(N{+}M)$ monomer folds where a complex-based predictor needs $O(NM)$ operations. Experimentally, under epitope-disjoint evaluation with six retrained baselines, EMBER is first on every metric under all four folding tools, by 0.9 to 14.4% in micro-AUROC, 18.5 to 25.3% in micro-AUPRC and 10.6 to 24.1% in MCC. Its ranking is also up to 85% more stable across folding tools.

0.42

InstructPro2: Natural Language and Biological Grounding Guided De Novo Protein Design

cs.LG ·2026-10-14 ·Charles Novak, Zhenqiao Song, Chuan Li, Jianwen Xie, Lei Li
similarity 0.56
Abstract · 19 pages, 6 figures

The ability to generate proteins with desired functions is a central goal of computational biology. Although natural language can express diverse design objectives, existing protein generation methods often support only narrow tasks or make limited use of biological constraints. We develop InstructPro2 to translate natural-language design objectives into protein sequences while incorporating task-specific biological context. A text encoder captures the design instructions, while dedicated ligand and antigen encoders provide biological context to the sequence-generating decoder. For pretraining, we assemble InstructPro2Bench, comprising 205.7 million <function description, protein> pairs from UniProtKB. We subsequently adapt the model to ligand-binding protein and antibody design. On functional protein generation benchmarks, InstructPro2 outperforms Pinal, the strongest baseline, achieving a functional recovery F1 of 74.8 versus 62.2 and lowering global RMSD from 5.33A to 3.04A. For antibody design, the model obtains a DockQ score of 0.39, while ligand-binding protein design reaches a docking success rate of 72.6%. These findings highlight how integrating language-based instructions with biological conditioning can extend protein generation to distinct design settings.

0.14

Revisiting Structure-Based Filtering for AI-Designed Antibodies: Opportunities, Limits, and What Matters

cs.CE ·2026-10-16 ·Langzhang Liang, Juncheng Qian, Xiaojie Ma, Mingxi Zou, Yinghui Xu +2 more
similarity 0.54
Abstract · 29 pages, 4 figures

AI antibody design can generate far more candidates than can be experimentally tested, making post-generation filtering a central bottleneck. We study whether structure-prediction outputs can help prioritize AI-designed antibodies for experimental validation. We evaluate this problem on 4,184 experimentally characterized antibody-antigen pairs, combining newly generated wet-lab measurements with curated affinity data across diverse antigens and assay settings. We introduce two complementary filtering signals: Regional Interaction Contrast (RIC), which captures support for the predicted antibody-antigen interface, and Non-CDR Antibody Confidence (NAC), which measures antibody confidence outside the CDRs. Across AlphaFold 3, Protenix-v2, and ESMFold2, we find a striking difference in what information matters for filtering. Interface evidence is strongest when comparing candidates designed for different antigens, whereas antibody-level reliability is substantially more informative for ranking candidates within the same antigen. In particular, non-CDR antibody confidence consistently outperforms whole-antibody confidence across predictors, revealing an unexpected source of filtering signal beyond the predicted interface. Finally, we examine the information encoded in the predictor outputs themselves. Predicted structures contain substantial but incomplete binding-related signal, revealing both the opportunities and limits of structure-based filtering: better metrics can exploit current predictors more effectively, but their performance ultimately remains constrained by what those predictors can distinguish.

0.32

TorchCraft: Unified binder design by inverting an all-atom structure predictor

cs.AI cs.CEcs.LG ·2026-09-17 ·TorchCraft Team, Yu Liu, Zhouhanyu Shen, Zhengyi Li, Xikun Huang +6 more
similarity 0.54
Abstract

All-atom structure predictors model diverse molecular interactions, but using their learned structural priors for binder design remains challenging. Here we present TorchCraft, a unified binder-design framework that optimizes sequence logits through a frozen all-atom predictor. Implemented in TorchFold, TorchCraft combines confidence, contact, geometric, and sequence-prior objectives within a shared optimization procedure for minibinders, framework-conditioned VHHs, cyclic peptides, and ligand-binding proteins. Using pretrained AlphaFold 3 weights, TorchCraft generated representative minibinders and VHHs with experimentally measured binding across four targets in each format, without post hoc sequence redesign. Computational benchmarks further demonstrated the framework's applicability to cyclic peptides and ligand-conditioned pocket design. TorchCraft extends predictor inversion to multiple binder formats and molecular contexts, providing a common framework for reusing all-atom structural priors in design.

0.10

Joint Discrete and SE(3) Diffusion for Protein Interface Design

cs.AI ·2026-10-10 ·Zhenqiao Song, Jianwen Xie, Lei Li
similarity 0.54
Abstract

The design of high-affinity, target-specific protein binders is central to the development of modern therapeutics. However, existing protein-generation methods remain limited in this setting, as many generated designs fail to simultaneously achieve geometric and physicochemical complementarity at binding interfaces. To address this challenge, we introduce PIDiff, a physicochemically enhanced multimodal diffusion framework for protein-protein complex design. PIDiff jointly designs target-conditioned protein sequences and structures by coupling diffusion in discrete sequence space with diffusion on the continuous (SE(3)) structural manifold. At its core, PIDiff employs PIFormer, a novel architecture that interleaves geometry-aware invariant point attention with global sequence self-attention. We further curate PIBench, a protein-protein complex dataset with diverse target scaffolds derived from the Protein Data Bank (PDB). We first pretrain PIDiff on PIBench and subsequently fine-tune it for two therapeutically relevant applications: minibinder design and antibody design. PPFrame consistently outperforms baseline methods across sequence design success rate, structure binding energy, and sequence-structure co-designability on all tasks.

0.15

Multimodal reasoning for broadly neutralizing antibody discovery from label-free human B cell repertoires across virus families

cs.AI q-bio.QMcs.CEq-bio.CB ·2026-10-02 ·Hantao Lou, Jianqing Zheng, Can Yue, Meihan Zhang, Yuanchao Bao +19 more
similarity 0.52
Abstract

Discovering broadly neutralizing antibodies (bnAbs) from human natural immune repertoires remains a fundamental challenge in immunology, hindered by: the extreme rarity of bnAb, incomplete understanding of their cellular origins across pathogens, and the inability of existing computational tools to generalize across emerging viral threats. Here we present ImmuneAgent, a closed-loop AI system that integrates multimodal reasoning with continual meta-learning and wet-lab feedback to overcome these barriers. Applied to screen the natural BCR repertoires from vaccinated or infected cohorts, the system achieves a ~55% neutralization antibody discovery rate (60 of 110 cloned candidates) and a ~11% bnAb yield (12 of 110), substantially outperforming a state-of-the-art sequence-based neutralization predictor or cofolding models evaluated at the same cloning budget. Five ImmuneAgent-discovered antibodies conferred 100% in vivo protection against lethal influenza challenge, comparable to the clinical-stage therapeutic MEDI8852. The system recovered the cellular and structural determinants of bnAb activity and identified FCRL5+CD27+ atypical memory B cells as a conserved bnAb reservoir and hydrophobic interface enrichment as a cross-viral structural signature, which generalized to unseen antigens, discovering human metapneumovirus (hMPV) cross-neutralizing and human papillomavirus (HPV)-neutralizing antibodies without antigen-specific sorting. These results validate that ImmuneAgent is a generalizable framework for rapid therapeutic antibody discovery against emerging viral threats.

0.20

RangeFinder: Predicting Ligand Property Ranges from Protein Pockets

cs.LG q-bio.BM ·2026-11-02 ·Alan Nadelsticher Ruvalcaba, Chris Alvin, Supratik Mukhopadhyay, Adam Bess
publishedcode/data similarity 0.52
Abstract · Accepted at the AI for Drug Discovery workshop --- NeurIPS 2026

Identifying ligands for a protein target requires searching a vast chemical space for a comparatively small set of compatible molecules. Existing machine learning approaches primarily address this problem by generating candidate ligands or scoring individual protein-ligand pairs, but provide limited information about the broader chemical space compatible with a binding pocket. We introduce RangeFinder, an SE(3)-equivariant transformer pocket-level model, trained and evaluated on BioLiP2 data, that predicts ranges over nine physicochemical ligand properties directly from pocket structure, chemistry, and evolutionary context. Using an intersection-over-union objective and evaluation metric (range-IoU), RangeFinder achieves a range-IoU of $0.464 \pm 0.002$, outperforming all deployable baselines while requiring only $12.2$ ms per pocket. We also quantify our method's ability to reduce the ligand search space while retaining compatible binders; in this regard, RangeFinder achieves a Reduction-Recall F-Score of $0.543 \pm 0.011$ --- once again outperforming all deployable baselines. Ablation experiments indicate that RangeFinder's performance depends more strongly on the density and quality of ligand supervision than on any individual input modality or specialized training strategy. Together, these results position RangeFinder as an inexpensive and effective molecular filtering prior, with demonstrated potential in narrowing the ligand search space of target pockets before docking, generation, or synthesis. The code for this project can be found at: https://github.com/alannadels/RangeFinder.

0.45